Next, we will briefly discuss how the altered cellular distribution of CRM1 cargoes contributes to a particular cancer hallmark, and how CRM1 inhibition may reverse these processes, hopefully bringing some insights into CRM1 inhibitors’ broad-spectrum anti-cancer activity. Here, XPO1 is linked to cancer.